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ABSTRACT 
Background: The concept of clinical control in COPD has been developed to help in 
treatment decisions, but it requires validation in prospective studies.  
Method: This international, multicenter, prospective study aimed to validate the concept of 
control in COPD [control= stability (no exacerbations or impairment in CAT scores) + low 
impact (low level of symptoms)]. We investigated the level of control, compared 
characteristics of patients according to the control status, and performed a sensitivity 
analysis of the levels of control using either clinical criteria or questionnaires (COPD 
Assessment Test –CAT- or Clinical COPD Questionnaire –CCQ-). 
Results: A total of 314 patients were analysed (mean age 68.5 years and mean FEV1(%)= 
52.6%). According to the prespecified criteria 21% of patients were classified as controlled, 
all of them with mild/moderate COPD (Body mass index, Obstruction, Dyspnea and 
Exacerbations, –BODEx- index <5). A high level of dyspnea, a high CAT score or an 
exacerbation in the previous 3 months were found, using univariate analysis, to be the main 
reasons for patients not being classified as controlled. Multivariate analysis showed that 
female sex, chronic bronchitis and having exacerbations in the previous year were associated 
with uncontrolled COPD. Changing the severity cut off of BODEx from 5 to 3 did not 
change significantly the percentage of patients fulfilling the criteria of control. 
Conclusions: The proposed criteria of control were only fulfilled by 21% of patients. The 
suggested cut offs and their predictive value for poor outcomes need to be refined in 
prospective studies.    
 
KEYWORDS: COPD; control; CAT; CCQ; Outcomes. 
 
INTRODUCTION 
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Chronic obstructive pulmonary disease (COPD) is a heterogeneous condition requiring 
therapeutic management to be tailored to the clinical characteristics and disease severity of 
the individual patient (1,2). Treatment of COPD should be aimed at  controlling symptoms 
and reducing the risk of exacerbations (3,4); if these objectives are achieved we could 
consider that the disease is under control, regardless of the degree of impairment in lung 
function or health status (5).  
Unfortunately, even with pharmacological and non-pharmacological treatment strategies, 
patients with COPD usually have daily symptoms and suffer exacerbations of the condition 
(6); therefore, there is a need for objective measures to evaluate the level of control of the 
disease. The concept of control has been well developed in asthma (7), however, in COPD 
the different characteristics of the disease have made this concept elusive. Objective 
physiological measures of lung function and multicomponent indices are very helpful in 
evaluating the stage of the disease and establishing a prognosis (8), and the use of patient 
reported outcomes (PROs) helps us to understand the impact of the disease on health-related 
quality of life, sleep quality and mood, among others (9); however, these measures are not 
sensitive enough to guide treatment decisions. 
It is well known that patients with the same level of lung function impairment may have 
very different symptom burdens, or patients with the same health status may have different 
risks of exacerbations (10); therefore, the concept of control should incorporate the main 
objectives of treatment of COPD: reduction in symptoms and reduction in exacerbation risk. 
Recently, it has been proposed that control in COPD reflects the impact and stability of the 
condition (5,11). Impact is related to the manifestations of the disease at the time of medical 
consultation and stability is related to the changes of the clinical status of the patient over 
time, including the presence of exacerbations.   
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Control in COPD would be a conceptual dimension requiring demonstration of both low 
impact and clinical stability of disease. The developers of the concept hypothesize that 
patients who have controlled COPD will have better clinical outcomes (reduced frequency 
of exacerbations and mortality, and improved health-related quality of life), as well as a 
slower decline in lung function and reduced COPD-related healthcare costs. 
The current study was designed with the objective to validate the concept of control as a 
valid and reliable prognostic measure. In the current work, we present the design of the 
study, the baseline characteristics of the population and their control status according to the 
proposed criteria, along with the changes in control status when the criteria for impact 
and/or stability are modified. 
 
METHOD 
Study design 
This international, multicenter, prospective study of a cohort of patients with COPD aimed 
to validate the concept of clinical control in COPD. It was a 21 month prospective 
observational study, comprising 5 evaluation points: one screening evaluation (V-1), one 
baseline visit after 3 months (V0) and 3 follow-up visits at 6 months intervals (V1-V3). At 
screening visit, eligible patients had a full clinical assessment, including evaluation of: 
current smoking status, presence of comorbidities, spirometry and baseline questionnaires. 
At baseline visit, the control status of the patients was assessed as indicated below. 
Throughout the study, patients were managed according to the criteria of the investigators. 
The primary study outcome is the difference in (annualized) rates of a composite endpoint 
for patients controlled versus uncontrolled at baseline, and will be measured over the 18-
month follow-up period. The composite endpoint is defined as occurrence of any of the 
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following: an ambulatory exacerbation, an emergency room attendance or hospital 
admission due to an exacerbation, or death. 
In this work, we present the results of V-1 and V0 visits in terms of baseline characteristics 
of the included patients, the levels of clinical control according to the prespecified criteria, 
and the comparison of characteristics of patients according control status. A sensitivity 
analysis of the levels of control was performed using either clinical criteria or 
questionnaires, and after modifying the classification of severity of COPD at screening. 
This study was conducted in full accordance with the International Conference on 
Harmonisation (ICH) Good Clinical Practice (GCP) Consolidated Guideline (E6) and any 
applicable national and local laws and regulations (e.g. European Union [EU] Directive 
2001/20/EC and 2005/28/EC). The study was approved by the local Research and Ethics 
Committees of each participating research site and all patients provided written informed 
consent. The data for UK was obtained from the Optimum Patient Care Research Database 
(OPCRD) and permission to access and link UK data to anonymous electronic medical 
records was obtained from the Health Research Authority for clinical research use (REC 
reference 15/EM/0150). This study was registered with the European Network of Centres for 
Pharmacoepidemiology and Pharmacovigilance (ENCePP), Register Number EUPAS10679. 
Population 
Eligible patients had to have spirometry-defined COPD (i.e. post-bronchodilator 
FEV1/FVC<0.7), be over 40 years of age, be current or ex-smokers with at least 10 pack-
years of smoking exposure, and be in a stable clinical state (as judged by the investigator) at 
point of recruitment. Patients were excluded from the trial if any of the following were true, 
they: 1) Had any chronic concomitant respiratory condition other than asthma or 
bronchiectasis (e.g. cystic fibrosis, lung fibrosis); 2) Had severe comorbidity with a life 
expectancy shorter than 2 years; 3) Were unable to understand the instructions of the study 
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or to fill in the questionnaires; 4) Were unwilling to sign the informed consent; 5) Were 
participating in another clinical study or clinical trial. 
Measurements 
The prespecified criteria of clinical control were described by Soler-Cataluña et al. (5,11). 
Briefly, a patient was considered controlled when disease was clinically stable and of low 
impact, when adjusted for the level of disease severity. Stability was defined by the absence 
of exacerbations in the previous 3 months plus stability in the COPD Assessment Test 
(CAT), defined as any change that was less than a 3 unit increase (12). For comparison, we 
also considered a change in the Clinical COPD Questionnaire (CCQ) scores of 0.4 units or 
less as an alternative criterion for stability (13). Impact was classified as low or high 
according to the information collected on sputum (presence and colour), breathlessness, 
daily physical activity and (patient reported) rescue medication. In summary, “controlled” 
was defined as:  
1) “low impact”, based on clinical symptoms and CAT score (Table 1), 
AND  
2) “stable”, defined as no exacerbations and no substantial increase (>3 units) in CAT score 
in the previous 3 months.  
Evaluation of impact was adjusted by disease severity according to the Body Mass Index, 
Obstruction, Dyspnea, and Exacerbations (BODEx) indices (14). Patients with BODEx 4 or 
less were classified as mild/moderate and those with 5 or more as severe.   
The control status of the patients was established according to the clinical and questionnaire 
data obtained at baseline visit (V0) and the history of exacerbations and changes in 
questionnaires’ scores between screening visit (V-1) and V0.  
The CAT is a specific questionnaire that measures the impact of disease in a patient using 8 
questions which evaluate cough, expectoration, dyspnea, chest tightness, patient confidence, 
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limitations in daily activities, quality of sleep and energy. The CAT score ranges from 0 to 
40, and the higher the score the worse the health status of the patient (15). The CCQ has 
three domains: symptoms (4 items), functional status (4 items) and mental state (2 items), 
graded on a 7-point Likert scale from 0 to 6 (0=no impairment) (16). Breathlessness was 
measured by the modified Medical Research Council (mMRC) dyspnea scale (17) and 
physical activity by self-declared minutes walking per day, as previously described (18). 
Comorbidities were assessed with the age-adjusted Charlson index (19). 
A COPD exacerbation was defined as of any one of the following: acute use of oral 
corticosteroids and/or a course of antibiotics, for lower respiratory symptoms or within 5 
days of an unscheduled hospital admission/ emergency department attendance for acute 
respiratory symptoms. 
Statistical analysis 
The sample size calculation was based on a previous pilot study in tertiary hospitals in 
Spain, in which 55% of patients with COPD were controlled based on the proposed criteria 
(unpublished data). We performed a conservative approach using the expected frequency of 
exacerbations according to results from the ECLIPSE Study, in which the annualized rate of 
exacerbations was 1.2 per patient (20). We hypothesize that, in controlled COPD patients, 
this annual rate could be 40% lower (0.72 per patient). Accepting an alpha risk of 5% and a 
beta risk of 10% in a two-sided test, a total of 285 COPD patients will be necessary to find 
this annualized incidence ratio difference statistically significant between controlled and 
uncontrolled patients. With an expected drop-out rate of 15%, a total of 328 patients should 
be enrolled in the study. Sample size has been calculated with !NI2IS macro (SPSS V23).  
Absolute frequencies and percentages were used for comparisons of qualitative variables. 
The description of quantitative variables was performed using the mean and standard 
deviation (SD). The Kolmogorov-Smirnov test was used to assess the normality of 
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distributions. In the case of quantitative variables, the comparison of the characteristics 
between controlled versus uncontrolled patients was carried out using the Student t-test 
(Mann-Whitney U-test if normality was not assumed). The Chi-squared test (Fisher test for 
frequencies <5) was employed for the comparison of categorical variables.  
A predictive model was developed using backward stepwise logistic regression analysis 
including control as a dependent variable. Clinical and demographic variables, not related to 
the definition of control and with a significance level <0.2 in the univariate analysis, were 
included as independent variables. The results are reported with odds ratios (OR) with a 
95% confidence interval (CI) and p-values. The Hosmer-Lemeshow goodness-of-fit test was 
performed to assess the overall fit of the model. For all tests, p-values <0.05 were 
considered statistically significant. All analyses were performed using SPSS (V 23). 
A sensitivity analysis of the control criteria was performed. The differences in the frequency 
of control according to different criteria for impact and/or stability were investigated. Impact 
was defined by using only clinical criteria, CAT or CCQ scores and the combinations of 
clinical criteria plus either CAT or CCQ scores. Stability was defined by the history of 
exacerbations alone or changes in CAT or CCQ scores, or combinations of history of 
exacerbations plus either changes in CAT or CCQ. All these possibilities were compared 
with the prespecified definition: impact by clinical criteria and stability by history of 
exacerbations and changes in CAT scores.  
 
RESULTS 
Population 
A total of 349 patients were recruited, of which 314 (90%) completed the baseline visit and 
could be evaluated for control status and constitute the population of this study. The mean 
age was 68.5 years [standard deviation (SD)= 8.7], 47 (15%) were managed in primary care 
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and the remaining patients in specialized centers, 72.5% were male and mean FEV1 was 
52.6% of predicted (18). A total of 276 (87.8%) were classified as having mild/moderate 
COPD and 39 (12.2%) as severe based on the BODEx index. The characteristics of the 
population are described in Table 2.  
 
Control status, characteristics and treatment of controlled and uncontrolled patients 
A total of 67 (21%) of patients fulfilled the criteria of control, all of them classed as having 
mild/moderate disease. Comparison of characteristics of controlled versus uncontrolled 
patients are presented in Table 2. Uncontrolled patients were more frequently female, with 
more comorbidities, more chronic bronchitis, more exacerbations the previous year and 
worse FEV1.  
Regarding pharmacological treatments, uncontrolled patients were more frequently using 
inhaled corticosteroids (ICS), in particular as part of triple therapy (Long-acting beta-2 
agonist (LABA)/ICS/long-acting antimuscarinic agent (LAMA)) (Table 3). 
Factors accounting for uncontrolled status of patients. 
Uncontrolled status may be due to high impact and/or instability of disease. We analysed the 
number of patients that were classified as high impact based on the different clinical criteria 
and questionnaire scores. mMRC was the most frequent criterion not fulfilled by patients 
(36.7% of mild/moderate and 84.6% of severe patients). More than half of the patients of 
both degrees of severity did not fulfil the criteria of control for the CAT score (Table 4). 
 Similarly, we evaluated the number of patients that were classified as instable based on the  
presence of exacerbations or large changes in questionnaire scores between V-1 and V0. Up 
to 51.2% of severe and 17.7% of mild/moderate patients experienced an exacerbation in the 
previous 3 months and were therefore not considered stable. Regarding CAT, 31.7% and 
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38.4% of mild/moderate and severe patients, respectively, experienced a change in CAT 
scores greater than the prespecified threshold (Table 4).    
Factors associated with control. Multivariate analysis 
A backward logistic multivariate model was developed with control as independent variable, 
and clinical and demographic variables, not related to the definition of control, as dependent 
variables. The adjusted model showed that male sex, absence of chronic bronchitis and no 
exacerbations in the previous year were independently and significantly associated with 
control (Table 5). This model showed good goodness-of-fit (Lemeshow p=0.825). 
Sensitivity analysis: Impact of using different criteria for impact and stability 
No large changes in the frequency of controlled patients were observed in the sensitivity 
analysis with different criteria for impact and stability, based either on clinical symptoms or 
questionnaire scores. The percentage of control ranged from a minimum of 13% with the 
more stringent criteria to a maximum of 32% compared with 21% with the prespecified 
criteria.  
When patients were classified as severe based on a BODEx index of 3 or more, the 
percentage of controlled patients similarly ranged from 17% to 37% (Table 6). 
 
DISCUSSION 
Our study is the first attempt to prospectively evaluate the validity of the concept of control 
of COPD for clinical practice. In the current analysis, we have observed that the proposed 
criteria for control were very restrictive; only 21% of a group of patients with COPD of 
different degrees of severity, 85% of which were followed in specialized centers, fulfilled 
the criteria required to be considered controlled. In the mild/moderate subgroup of patients 
approximately two thirds did not fulfil the clinical criteria of low impact and 42% were 
classified as unstable; therefore only around one quarter were defined as controlled. 
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Regarding severe patients, only one out of 39 was considered to have a low impact and 
finally no patients could be classified as controlled. Interestingly, changing the threshold of 
severity from 5 to 3 in the BODEx index did not change significantly the number of patients 
that fulfilled the criteria of control. Female sex, presence of chronic bronchitis and having 
exacerbations in the previous year were significantly and independently associated with 
uncontrolled status. 
These results are similar to those obtained in a retrospective analysis of the Optimum Patient 
Care Research Database (OPCRD) in the UK (21). Using the scores of the CAT 
questionnaire and some proxies for the clinical criteria of impact, only 4.5% of that primary 
care population of patients with COPD could be classified as controlled. Interestingly, 
controlled patients had a significantly reduced risk of future exacerbations, suggesting that 
the concept of control is valid as a predictor of poor outcomes (21). In the present analysis 
we explored the characteristics of controlled versus uncontrolled patients and the impact of 
different criteria for the classification of control; however, the final validation of the best 
criteria for clinical control will require the evaluation of the complete follow-up of the 
cohort. 
Soler-Cataluña et al. (5) proposed the concept of control of COPD to help in clinical 
decisions about treatment of the disease. This new concept was composed of: a) the impact 
of the disease on the patient at the time of consultation measured by the level of symptoms, 
the use of rescue medication and the level of regular physical activity, or alternatively with 
the use of a short questionnaire (CAT or CCQ), and b) the stability measured by the changes 
in the questionnaire scores (either CAT or CCQ) and exacerbations in the previous 3 
months.  
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These easy to obtain measurements should be predictive of future outcomes and sensitive 
enough to change with therapy. In order to validate the concept of control and establish the 
best thresholds for impact and stability, this prospective, international study was conducted.  
From the analysis of the baseline data, we can conclude that the proposed criteria require 
some refinement, in particular for severe patients. The thresholds of physical activity and 
rescue medication seem to be well calibrated, since only around one third of patients did not 
reach that level. However, 84% of severe patients were classified as high impact due to the 
criterion of dyspnea. Similarly, the cut offs suggested for CAT and CCQ scores seem to be 
very restrictive as less than 50% of patients could be considered as having low impact 
according to their questionnaire scores. Although the CAT score has been demonstrated to 
be the best predictor of the risk of future exacerbations compared with other PROs (22), the 
best threshold for increased risk is yet to be defined (23,24). In the previous database study 
using the OPCRD, the authors could not identify a value of the CAT score with enough 
predictive value for future exacerbations (21). The results of the follow-up of the current 
study may help us to identify a cut off CAT score that provides a measure of low/high 
clinical impact with prognostic implications. The suggested change of 2 units in the CAT 
score as a threshold of stability was considered based on the identification of the minimum 
clinically important difference (12); however, Pothirat et al. (25) suggested a change of 4 
units as the optimum cut off point score for the detection of acute deterioration in health 
status with a sensitivity, specificity and accuracy of 76.8%, 83.6% and 82.4%, respectively. 
Similarly, a change of less than 4 units in the CAT score from admission to discharge was 
significantly and independently associated with increased risk of clinical failure in the three 
months following discharge of exacerbated COPD patients (26). Previous work in over 
3,700 patients has suggested that for every 10 point worsening of CAT score there is a 28% 
greater risk of 2 or more exacerbations in the following year (27). New prospective studies 
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may help to establish the best cut off for changes in CAT scores as a predictor of poor 
outcomes in COPD. 
An individual analysis of the predictive value of the different proposed clinical criteria is 
also required. Sputum is the variable that has shown a lowest discriminative property for the 
level of impact. In contrast, having chronic bronchitis was associated, in multivariate 
analysis, with a lower probability of control. Chronic bronchitis is a well recognized risk 
factor for exacerbations (28) but the future risk associated with the quantity and 
characteristics of sputum during the clinical visit may not be significant or may be irrelevant 
in the context of the other proposed criteria for impact.  
In addition to chronic bronchitis, female sex and having exacerbations the previous year 
were identified as variables significantly associated with uncontrolled status in multivariate 
analysis. It has previously been reported that women with COPD present with more 
symptoms and worse health status compared with men with similar degree of airflow 
obstruction (29). History of previous exacerbations is also associated with worse health 
status (30) and is the best predictor of future exacerbations (20). 
We performed an exploratory sensitivity analysis to investigate the changes in the 
percentage of controlled patients following the changes in the criteria used for impact and 
stability. According to the prespecified criteria; i.e. low impact by clinical criteria and 
stability based on the absence in exacerbations and stability in the CAT score, only 21% of 
patients were classified as controlled, all of them with mild/moderate disease. Using more 
restrictive criteria requiring low impact by both clinical criteria and low CAT or CCQ 
scores, only 13% could be considered controlled. On the contrary, when only CAT scores 
were used to evaluate low impact and stability, up to 32% of patients reached the threshold 
of control, exactly the same 32% were classified as controlled when impact was based on 
clinical criteria and stability only on the absence of exacerbations in the previous 3 months. 
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Interestingly, these percentages did not change significantly when the severity of patients 
was classified with a cut off of 3 instead of 5 in the BODEx index, indicating that the low 
percentage of controlled patients was not related to the classification of severity. 
Alternatively, it can be speculated that there is no significant difference in the severity or 
prognosis between BODEx 3 and 5, and therefore other cut offs should be explored in the 
future.  
CONCLUSIONS 
In conclusion, the current proposed criteria for clinical control of COPD appear to be too 
restrictive. Changes in the classification of severity of COPD based on the BODEx index 
have very limited influence in the classification of controlled patients. In contrast the pre-
specified cut offs of symptoms, physical activity and questionnaire scores may require 
refinement based in the results of the prospective follow-up phase of the study.   
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Table 1. Criteria used to define low/high impact in COPD based on clinical data and scores 
of CAT or CCQ questionnaires. 
 
 Mild to moderate severity 
(BODEx ≤ 4 points) 
Severe/very severe COPD 
(BODEx ≥ 5 points) 
 Low impact High impact Low impact High impact 
Clinical evaluation: 
Dyspnea (mMRC) 0 – 1 ≥ 2 0 - 2 ≥ 3 
Rescue medication ≤ 3 times in the 
last week 
> 3 times in 
the last week 
≤ 2 times a day > 2 times a 
day 
Daily physical activity* 
(time walked per day) 
≥ 60 min < 60 min ≥ 30 min < 30 min 
Sputum color Absent or White Dark Absent or White Dark 
Questionnaires: 
- CAT ≤ 10 >10 ≤ 20 >20 
- CCQ ≤ 1 >1 ≤ 2 >2 
 
Footnote: mMRC: modified Medical Research Council; CAT: COPD assessment test; 
CCQ: clinical COPD questionnaire 
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Table 2. Demographic and clinical characteristics of the population and comparison 
between controlled and uncontrolled patients. 
 All  
(n=314) 
Controlled  
(n=67) 
Uncontrolled 
(n=247) 
P value 
Age, years  68.5 (8.7) 67.9 (8.5) 68.7 0.53 
Sex, men (%) 225 (72.5) 58 (89.2) 167 (68.1) 0.001 
Living status (%): 
Alone 
Couple or relatives 
 
60 (19.3) 
248 (80) 
 
8 (12.3) 
56 (86.5) 
 
52 (21.1) 
192 (77.3) 
 
0.09 
Education (%): 
Up to primary 
Secondary 
Some university  
 
95 (30.2) 
157 (50) 
61 (19.4) 
 
13 (19.4) 
33 (49.3) 
21 (31.3) 
 
82 (33.2) 
124 (50.2) 
40 (16.2) 
 
0.14 
Active smokers (%) 82 (26.1) 49 (73.1) 180 (72.9) 0.66 
Pack-years 47.7 (31.1) 42.7 (23.2) 49.7 (34.1) 0.08 
BMI (Kg/m2) 26.4 (5.3) 25.3 (4.9) 26.7 (5.4) 0.09 
Chronic bronchitis 
(%) 
162 (61.3) 27 (48.2) 135 (73.5) 0.023 
Emphysema (%) 198 (75) 45 (80.3) 153 (73.5) 0.29 
ACO (%) 30 (9.6) 8 (11.9) 22 (8.9) 0.46 
Bronchiectasis (%) 40 (12.8) 11 (16.6) 29 (11.8) 0.29 
Charlson index 4.2 (1.6) 3.9 (1.7) 4.3 (1.6) 0.049 
mMRC 1.62 (1) 0.85 (0.3) 1.83 (1) <0.001 
FVC, mL 
FVC (%) 
FEV1, mL 
FEV1 (%) 
2880 (892) 
67.5 (14.5) 
1489 (582) 
52.6 (18) 
3189 (953) 
71.6 (16.1) 
1758 (633) 
58.3 (18.3) 
2780 (860) 
65.8 (14.1) 
1416 (546) 
51 (17.7) 
0.002 
0.019 
<0.001 
0.003 
Exacerbations in the 
previous year 
1.27 (2.7) 0.54 (1.2) 1.47 (3) 0.004 
BODEx index 2.3 (1.8) 1.3 (1.2) 2.6 (1.8) <0.001 
CAT score 14.3 (8.7) 12.2 (7.6) 14.8 (8.9) 0.043 
CCQ score 2.03 (1.3) 1.77 (1.3) 2.1 (1.3) 0.033 
Minutes walked/day 82.2 (76.6) 117.7 (56) 72.3 (78.7) <0.001 
 
Footnote: Values are mean (SD, except otherwise indicated. BMI: Body mass index; ACO: 
Asthma-COPD overlap; mMRC: modified Medical Research Council; CAT: COPD 
assessment test; CCQ: clinical COPD questionnaire; FVC: Forced vital capacity; FEV1: 
Forced expiratory volume in 1 second. 
  
25 
Table 3. Pharmacologic treatment for COPD of controlled and uncontrolled patients 
 
 All  
(n=314) 
Controlled 
(n=67) 
Uncontrolled 
(n=247) 
P value 
SABA 55.9 43.6 59.1 0.04 
SAMA 22.8 10.9 25.9 0.018 
LABA 73.1 63.6 75.6 0.052 
LAMA 71.4 72.7 71.1 0.80 
ICS 38.8 25.7 42.2 0.014 
Theophylline 6 0 7.7 0.020 
Roflumilast 3.8 5.4 3.3 0.47 
Macrolides 1.1 0 1.4 0.37 
LTOT 6.7 3 7.7 0.17 
Influenza vaccine 52.1 36.3 56.2 0.009 
Antipneumococcal vaccine 36.5 20 40.9 0.004 
Treatment patterns 
SAMA/SABA alone or in 
combination 
1.1 1.8 1 0.60 
LABA alone 10.5 12.4 10.2 0.66 
LAMA alone 18.3 25.8 16.3 0.07 
ICS alone 0.6 0 0.8 0.46 
LABA/LAMA 26.3 28.8 25.6 0.60 
ICS/LABA 11.2 7.6 12.2 0.29 
ICS/LAMA 1.9 3 1.6 0.46 
ICS/LABA/LAMA 25 15.2 27.6 0.037 
 
Footnote: Values in percentages, %. SABA: short-acting beta-2 agonists; SAMA: Short-
acting antimuscarinic agents; LABA: Long-acting beta-2 agonists; LAMA: Long-acting 
antimuscarinic agents; ICS: Inhaled corticosteroids; LTOT: Long-term oxygen therapy.  
  
26 
Table 4. Factors accounting for the uncontrolled status (high impact or instability) of the 
COPD patients by level of severity. 
 
 Patients with high impact or instability  
due to: 
 
All  
(n=314)  Mild/moderate 
(n=276) 
Severe  
(n=39) 
Impact variables 
Dyspnea (mMRC) 101 (36.7) 33 (84.6) 134 (42.6) 
Rescue medication 60 (21.7) 14 (35.9) 74 (23.5) 
Physical activity 86 (31.1) 12 (30.7) 98 (31.2) 
Sputum  42 (15.2) 10 (25.6) 52 (16.6) 
Any clinical criteria 173 (62.7) 38 (97.4) 211 (67.2) 
CAT score 165 (59.8) 23 (58.9) 188 (59.8) 
CCQ score 189 (68.5) 29 (74.3) 218 (66.5) 
Stability variables 
Exacerbations 49 (17.7) 20 (51.2) 69 (21.9) 
Changes in CAT 87 (31.7) 15 (38.4) 102 (32.6) 
Changes in CCQ 127 (46.3) 19 (48.7) 146 (46.6) 
Any exacerbations or 
changes in CAT 
116 (42.2) 26 (66.6) 142 (45.2) 
Uncontrolled 208 (75.6) 39 (100) 247 (78.6) 
 
Footnote: Values are n (%). Percentages calculated on non-missing data.  
CAT indicates COPD assessment test; CCQ, clinical COPD questionnaire; mMRC modified 
Medical Research Council. 
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Table  5. Backward logistic multivariate model to control. 
 
 Unadjusted OR 
(CI95%) 
P value Adjusted OR 
(CI95%) 
P value 
Age, years 0.99 (0.96-0.02) 0.53   
Sex (male) 3.87 (1.68-8.86) 0.001 3.57 (1.16-10.92) 0.019 
Living alone 0.52 (0.23-1.16) 0.09   
Higher academic education 2.24 (1.09-4.59) 0.02   
BMI, Kg/m2 0.94 (0.90-1.002) 0.057   
Charlson index 0.85 (0.69-0.95) 0.049   
Chronic bronchitis 0.50 (0.27-0.91) 0.024 0.55 (0.29-0.93) 0.04 
Previous exacerbations 0.41 (0.22-0.77) 0.005 0.45 (0.22-0.91) 0.049 
 
Footnote: OR: odds ratio; CI: Confidence interval; BMI: Body mass index 
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Table 6. Evaluation of low impact, stability and control of COPD by using different criteria, either clinical, CAT or CCQ questionnaires.  
 
 Impact: 
clinical1 
Stability: 
EX 
Impact: 
CAT 
Stability: 
CAT 
Impact: 
CCQ 
Stability: 
CCQ 
Impact: 
clinical1 
Stability: 
EX & CAT 
Impact: 
CAT 
Stability: 
EX & CAT 
Impact: 
clinical1 & 
CAT 
Stability: 
EX & CAT 
Impact: 
clinical1 & 
CCQ 
Stability: 
EX & CCQ 
BODEx ≤4 versus ≥5        
Low Clinical Impact 104 (33) 127 (40) 91 (29) 104 (33) 127 (40) 55 (18) 44 (14) 
Stable 246 (78) 211 (67) 215 (70) 172 (55) 172 (55) 172 (55) 177 (57) 
Control of COPD 99 (32) 101 (32) 83 (27) 67 (21) 89 (28) 42 (13) 40 (13) 
BODEx ≤2 versus ≥3        
Low Clinical impact 126 (40) 171 (54) 129 (42) 126 (40) 171 (54) 82 (26) 63 (20) 
Stable 246 (78) 172 (55) 215 (70) 172 (55) 172 (55) 172 (55) 177 (57) 
Control of COPD 117 (37) 117 (37) 113 (37) 83 (27) 117 (37) 62 (20) 53 (17) 
 
Footnote: Values are n (%). Percentages calculated on non-missing data. 
CAT indicates COPD assessment test; CCQ, clinical COPD questionnaire; EX, exacerbations; COPD, chronic obstructive pulmonary disease; 
BODEx: Body mass index, Obstruction, Dyspnea and Exacerbations index. 
1  Clinical impact is defined using  dyspnea (mMRC), rescue medication, daily physical activity and sputum color. 
 
